Figure 7. Rapamycin and Triciribine inhibit the self-renewal ability of the neuroblastoma SH-SY5Y cancer stem/progenitor cells.

SFU obtained from serially passaged SH-SY5Y neurospheres over five generations is shown under untreated conditions (taken as control) and with 20 nM Rapamycin and 20 μM Triciribine-treated condition (treated once at G5) (left panels of charts A and B). Neuroblastoma CSC were enriched from SH-SY5Y cell line and treated with either Rapamycin (20 nM) (A) or Triciribine (20 μM) (B). After each propagation, cells that were initially treated with Rapamycin, Triciribine or media (control) were seeded into separate wells and exposed to control or treatment conditions (right panels of charts A and B). Spheres were propagated for five generations and results are expressed as SFU. Data represent an average of three independent experiments. The data are reported as mean ± SEM.